BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee BY, McGlone SM. Pricing of new vaccines. Hum Vaccin 2010;6:619-26. [PMID: 20861678 DOI: 10.4161/hv.6.8.11563] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Thomann B, Rushton J, Schuepbach-Regula G, Nathues H. Modeling Economic Effects of Vaccination Against Porcine Reproductive and Respiratory Syndrome: Impact of Vaccination Effectiveness, Vaccine Price, and Vaccination Coverage. Front Vet Sci 2020;7:500. [PMID: 32851052 DOI: 10.3389/fvets.2020.00500] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
2 Bacon KM, Hotez PJ, Kruchten SD, Kamhawi S, Bottazzi ME, Valenzuela JG, Lee BY. The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. Vaccine. 2013;31:480-486. [PMID: 23176979 DOI: 10.1016/j.vaccine.2012.11.032] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
3 Hussain R, Bukhari NI, Ur Rehman A, Hassali MA, Babar ZU. Vaccine Prices: A Systematic Review of Literature. Vaccines (Basel) 2020;8:E629. [PMID: 33137948 DOI: 10.3390/vaccines8040629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bartsch SM, Hotez PJ, Hertenstein DL, Diemert DJ, Zapf KM, Bottazzi ME, Bethony JM, Brown ST, Lee BY. Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. Vaccine 2016;34:2197-206. [PMID: 27002501 DOI: 10.1016/j.vaccine.2016.03.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
5 Bartsch SM, Lee BY. Economics and financing of vaccines for diarrheal diseases. Hum Vaccin Immunother 2014;10:1568-81. [PMID: 24755623 DOI: 10.4161/hv.28885] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jacobson SH. Vaccine pricing: how can we get it right? Expert Review of Vaccines 2014;11:1163-5. [DOI: 10.1586/erv.12.95] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lee BY, Wateska AR, Bailey RR, Tai JH, Bacon KM, Smith KJ. Forecasting the economic value of an Enterovirus 71 (EV71) vaccine. Vaccine 2010;28:7731-6. [PMID: 20923711 DOI: 10.1016/j.vaccine.2010.09.065] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
8 Rosales-mendoza S, Angulo C, Meza B. Food-Grade Organisms as Vaccine Biofactories and Oral Delivery Vehicles. Trends in Biotechnology 2016;34:124-36. [DOI: 10.1016/j.tibtech.2015.11.007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 11.6] [Reference Citation Analysis]
9 Lee BY, Connor DL, Kitchen SB, Bacon KM, Shah M, Brown ST, Bailey RR, Laosiritaworn Y, Burke DS, Cummings DA. Economic value of dengue vaccine in Thailand. Am J Trop Med Hyg 2011;84:764-72. [PMID: 21540387 DOI: 10.4269/ajtmh.2011.10-0624] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
10 Ridley DB, Bei X, Liebman EB. No Shot: US Vaccine Prices And Shortages. Health Affairs 2016;35:235-41. [DOI: 10.1377/hlthaff.2015.0420] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
11 Lee BY, Bartsch SM, Mvundura M, Jarrahian C, Zapf KM, Marinan K, Wateska AR, Snyder B, Swaminathan S, Jacoby E, Norman JJ, Prausnitz MR, Zehrung D. An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine. Vaccine 2015;33:4727-36. [PMID: 25772675 DOI: 10.1016/j.vaccine.2015.02.076] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
12 Bartsch SM, O'Shea KJ, Wedlock PT, Ferguson MC, Siegmund SS, Lee BY. Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting. Am J Prev Med 2021;60:360-8. [PMID: 33516583 DOI: 10.1016/j.amepre.2020.10.022] [Reference Citation Analysis]
13 Sciacchitano S, Bartolazzi A. Transparency in Negotiation of European Union With Big Pharma on COVID-19 Vaccines. Front Public Health 2021;9:647955. [PMID: 33681138 DOI: 10.3389/fpubh.2021.647955] [Reference Citation Analysis]
14 Herlihy N, Hutubessy R, Jit M. Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries. Health Affairs 2016;35:227-34. [DOI: 10.1377/hlthaff.2015.1411] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
15 Brooks A, Nunes JK, Garnett A, Biellik R, Leboulleux D, Birkett AJ, Loucq C. Aligning new interventions with developing country health systems: target product profiles, presentation, and clinical trial design. Glob Public Health 2012;7:931-45. [PMID: 22783872 DOI: 10.1080/17441692.2012.699088] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
16 Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012;30:7443-6. [PMID: 23084849 DOI: 10.1016/j.vaccine.2012.10.025] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 7.4] [Reference Citation Analysis]